




RealRate

PHARMACEUTICAL 2020

Mersana Therapeutics Inc.
Rank 100 of 362



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai



PHARMACEUTICAL 2020

Mersana Therapeutics Inc.
Rank 100 of 362



The relative strengths and weaknesses of Mersana Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Mersana Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 190% points. The greatest weakness of Mersana Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 106% points.

The company's Economic Capital Ratio, given in the ranking table, is -41%, being 261% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	101,326
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	24,070
Liabilities, Non-Current	5,153
Other Assets	4,051
Other Compr. Net Income	33
Other Expenses	0
Other Liabilities	0
Other Net Income	1,992
Property and Equipment	2,164
Research and Development	55,040
Revenues	42,123
Selling, General and Administrative Expense	17,283

Output Variable	Value in 1000 USD
Assets	107,541
Liabilities	29,223
Expenses	72,323
Stockholders Equity	78,318
Net Income	-28,208
Comprehensive Net Income	-28,192
Economic Capital Ratio	-41%

